169 related articles for article (PubMed ID: 7095921)
21. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
Johnston A; Henry JA; Warrington SJ; Hamer NA
Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of disopyramide in patients with chronic renal failure.
Francois B; Mallein R; Rondelet J; Lussignol M
Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of tinoridine after oral administration to healthy subjects and patients with renal failure.
Delhotal B; Flouvat B; Potaux L
Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):410-6. PubMed ID: 6605310
[TBL] [Abstract][Full Text] [Related]
25. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration].
De Graeve J; Kremers P; Gielen JE
Therapie; 1977; 32(2):195-204. PubMed ID: 898127
[No Abstract] [Full Text] [Related]
27. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
[TBL] [Abstract][Full Text] [Related]
28. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
Ericsson H; Hamrén B; Bergstrand S; Elebring M; Fryklund L; Heijer M; Ohman KP
Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated intravenous administration to rats.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):114-27. PubMed ID: 8720299
[TBL] [Abstract][Full Text] [Related]
31. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
32. Disopyramide pharmacokinetics during recovery from myocardial infarction.
Bryson SM; Cairns CJ; Whiting B
Br J Clin Pharmacol; 1982 Mar; 13(3):417-21. PubMed ID: 7059444
[TBL] [Abstract][Full Text] [Related]
33. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
Landmark K; Bredesen JE; Thaulow E; Simonsen S; Amlie JP
Eur J Clin Pharmacol; 1981 Feb; 19(3):187-92. PubMed ID: 7215416
[TBL] [Abstract][Full Text] [Related]
35. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
Bryson SM; Whiting B; Lawrence JR
Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
[TBL] [Abstract][Full Text] [Related]
37. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
Shaw LM; Doherty JU; Waxman HL; Josephson ME
Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
[TBL] [Abstract][Full Text] [Related]
38. Disposition kinetics of disopyramide in patients with renal insufficiency.
Shen DD; Cunningham JL; Shudo I; Azarnoff DL
Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
[TBL] [Abstract][Full Text] [Related]
39. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic-hemodynamic studies of disopyramide.
Abdollah H; Brien JF; Armstrong PW
J Cardiovasc Pharmacol; 1984; 6(1):28-34. PubMed ID: 6199608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]